Aldose reductase inhibition alters nodal Na+ currents and nerve conduction in human diabetics

Neurology

Volumn 66, Issue 10, 2006, Pages 1545-1549

  Misawa, S ^a   Kuwabara, S ^a   Kanai, K ^a   Tamura, N ^a   Nakata, M ^a   Sawai, S ^a   Yagui, K ^a   Hattori, T ^a  

^a CHIBA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATASE (POTASSIUM SODIUM); ALDEHYDE REDUCTASE; ALDOSE REDUCTASE INHIBITOR; EPALRESTAT; POLYOL; ANTIDIABETIC AGENT; DRUG DERIVATIVE; GLYCOSYLATED HEMOGLOBIN; INSULIN; RHODANINE; SODIUM; SODIUM CHANNEL; THIAZOLIDINE DERIVATIVE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DIABETES MELLITUS; DIABETIC NEUROPATHY; DISEASE SEVERITY; ENZYME INHIBITION; FEMALE; HUMAN; LATENT PERIOD; MALE; MEMBRANE CURRENT; MOTOR NERVE; NERVE CELL EXCITABILITY; NERVE CONDUCTION; NERVE FIBER; PRIORITY JOURNAL; SODIUM CURRENT; SURAL NERVE; CARPAL TUNNEL SYNDROME; DRUG ANTAGONISM; DRUG EFFECT; ENZYMOLOGY; INSULIN DEPENDENT DIABETES MELLITUS; ION TRANSPORT; MEDIAN NERVE; METABOLISM; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOPHYSIOLOGY; REACTION TIME;

ADULT; AGED; AGED, 80 AND OVER; ALDEHYDE REDUCTASE; CARPAL TUNNEL SYNDROME; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DIABETIC NEUROPATHIES; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; ION TRANSPORT; MALE; MEDIAN NERVE; MIDDLE AGED; NEURAL CONDUCTION; REACTION TIME; RHODANINE; SODIUM; SODIUM CHANNELS; THIAZOLIDINES;

EID: 33745398891     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/01.wnl.0000216260.39452.bf     Document Type: Article

References (32)

1. Gordois A, Scuffham P, Shearer A, et al. The health care costs of diabetic peripheral neuropathy in the US. Diabetes Care 2003;26:1790-1795.
2. Gordois A, Scuffham P, Shearer A, Oglesby A. The health care costs of diabetic nephropathy in the United States and the United Kingdom. J Diabetes Complications 2004;18:18-26.
3. Shearer A, Scuffham P, Gordois A, Oglesby A. Predicted costs and outcomes from reduced vibration detection in people with diabetes in the U.S. Diabetes Care 2003;26:2305-2310.
4. The DCCT Research Group. The effect of intensive insulin treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med 1993;329:977-986.
5. Sima AAF. Metabolic alterations of peripheral nerve in diabetes. Semin Neurol 1996;16:129-137.
6. Brismar T, Sima AAF, Greene DA. Reversible and irreversible nodal dysfunction in diabetic neuropathy. Ann Neurol 1987;1:504-507.
7. Brismar T. Abnormal Na-currents in diabetic rat nerve nodal membrane. Diabet Med 1993;10 (suppl 2):S110-S112.
8. Kitano Y, Kuwabara S, Misawa S, et al. The acute effects of glycemic control on axonal excitability in human diabetics. Ann Neurol 2004;56:462-467.
9. Misawa S, Kuwabara S, Ogawara K, et al. Hyperglycemia alters refractory period in human diabetic neuropathy. Clin Neurophysiol 2004;115:2525-2529.
10. Misawa S, Kuwabara S, Ogawara K, et al. Strength-duration properties and glycemic control in human diabetic motor nerves. Clin Neurophysiol 2005;116:254-258.
11. Sima AAF, Prashar A, Zhang WX, et al. Preventive effect of long-term aldose reductase inhibition (ponalrestat) on nerve conduction and sural nerve structure in the spontaneously diabetic Bio-Breeding rat. J Clin Invest 1990;85:1410-1420.
12. Yagihashi S, Yamagishi S, Wada R, et al. Neuropathy in diabetic mice overexpressing human aldose reductase and effects of aldose reductase inhibitor. Brain 2001;124:2448-2458.
13. Obrosova IG, Van Huysen C, Fathallah L, et al. An aldose reductase inhibitor reverses early diabetes-induced changes in peripheral nerve function, metabolism, and antioxidative defense. FASEB J 2002;16:123-125.
14. Sima AAF, Bril V, Nathaniel V, et al. Regeneration and repair of myelinated fibers in sural-nerve biopsy specimens from patients with diabetic neuropathy treated with sorbinil. N Engl J Med 1988;319:548-555.
15. Florkowski CM, Rowe BR, Nightingale S, Harvey TC, Barnett AH. Clinical and neurophysiological studies of aldose reductase inhibitor ponalrestat in chronic symptomatic diabetic peripheral neuropathy. Diabetes 1991;40:129-133.
16. Greene DA, Arezzo JC, Brown MB. Effect of aldose reductase inhibition on nerve conduction and morphometry in diabetic neuropathy. Zenarestat Study Group. Neurology 1999;53:580-591.
17. Crill WE. Persistent sodium current in mammalian central neurons. Annu Rev Physiol 1996;58:349-362.
18. Bostock H, Rothwell JC. Latent addition in motor and sensory fibres of human peripheral nerve. J Physiol (Lond) 1997;498:277-294.
19. Bostock H, Cikurel K, Burke D. Threshold tracking techniques in the study of human peripheral nerve. Muscle Nerve 1998;21:137-158.
20. Dyck PJ. Detection, characterization, and staging of polyneuropathy: assessed in diabetics. Muscle Nerve 1988;11:21-32.
21. Kiernan MC, Walters RJ, Andersen KV, et al. Nerve excitability changes in chronic renal failure indicate membrane depolarization due to hyperkalaemia. Brain 2002;125:1366-1378.
22. Andersen H, Stålberg E, Flack B. F-wave latency, the most sensitive nerve conduction parameter in patients with diabetes mellitus. Muscle Nerve 1997;20:1296-1302.
23. Lin CS, Chan JH, Pierrot-Deseilligny E, Burke D. Excitability of human muscle afferents studied using threshold tracking of the H reflex. J Physiol (Lond) 2002;545:661-669.
24. Kuwabara S, Bostock H, Ogawara K, et al. Excitability properties of human median axons measured at the motor point. Muscle Nerve 2004;29:227-233.
25. Mogyoros I, Kiernan MC, Burke D. Strength-duration properties of human peripheral nerve. Brain 1996;119:439-447.
26. Mogyoros I, Kiernan MC, Burke D, et al. Strength-duration properties of sensory and motor axons in amyotrophic lateral sclerosis. Brain 1998;121:851-859.
27. Bostock H. The strength-duration relationship for excitation of myelin-ated nerve: computed dependence on membrane parameters. J Physiol (Lond) 1983;341:59-74.
28. Kiernan MC, Burke D, Andersen KV, et al. Multiple measures of axonal excitability: a new approach in clinical testing. Muscle Nerve 2000;23:399-409.
29. Kuwabara S, Cappelen-Smith C, Lin C, et al. Excitability properties of median and peroneal motor axons. Muscle Nerve 2000;23:1365-1373.
30. + channel immunolocalization in peripheral mammalian axons and changes following nerve injury and neuroma formation. J Neurosci 1993;13:1976-1992.
31. Kikkawa Y, Kuwabara S, Misawa S, et al. The acute effects of glycemic control on nerve conduction in human diabetics. Clin Neurophysiol 2005;116:270-274.
32. Kohara N, Kimura J, Kaji R, et al. F-wave latency serves as the most reproducible measure in nerve conduction studies of diabetic polyneuropathy: multicentre analysis in healthy subjects and patients with diabetic polyneuropathy. Diabetologia 2000;43:915-921.